Xenon Pharmaceuticals' Epilepsy Drug Azetukalner Achieves Record-Breaking Trial Results, Paving Way for FDA Approval
Key Insights
Xenon Pharmaceuticals' azetukalner demonstrated a 53.2% reduction in seizures among treatment-resistant epilepsy (search) patients, representing the highest placebo-adjusted efficacy ever observed in a pivotal epilepsy study.
The late-stage trial of 380 patients showed 55% of participants experienced at least a 50% reduction in seizure activity, with the drug outperforming placebo by 42.7 percentage points over 12 weeks.
Xenon plans to submit a new drug application to the FDA in the second half of 2026, potentially bringing the 15th B.C.-developed therapy to market for the 3 million Americans living with epilepsy (search).
Xenon Pharmaceuticals Inc. has reported breakthrough results from its pivotal late-stage trial of azetukalner, an experimental epilepsy (search) treatment that achieved the highest placebo-adjusted efficacy ever observed in a pivotal epilepsy study. The Burnaby, B.C.-based company announced that patients taking a 25 mg dose of the drug experienced a 53.2% reduction in seizures over 12 weeks, which was 42.7 percentage points better than those receiving placebo.
The positive results sent Xenon's stock soaring 44.4% to US$60.56 per share on the Nasdaq, reinforcing its position as Canada's most valuable biotechnology company with a market capitalization of US$3.4 billion.
Unprecedented Clinical Efficacy
The 380-patient trial demonstrated remarkable efficacy in treating focal onset seizures (search), the most common form of epilepsy (search). Nearly 55% of patients on the 25 mg dose experienced a reduction in seizure activity of more than half, surpassing results from the company's previous 2021 trial of 325 patients.
"We are very happy to announce these data for azetukalner, which exceeded expectations and, to our knowledge, show the highest placebo-adjusted efficacy ever observed in a pivotal epilepsy (search) study," said Ian Mortimer, Xenon's chief executive officer.
The latest results improved upon Xenon's 2021 human trial, which showed patient seizures on the 25 mg pill dropped by 52.8% over an eight-week span, 34.6 percentage points more than people taking placebo. In that earlier study, 54.5% of participants had at least a 50% reduction in monthly seizure frequency.
Targeting Treatment-Resistant Patients
Azetukalner represents a novel approach to epilepsy (search) treatment, modulating the flow of potassium ions through electrical channels in the nervous system to temper excessive brain activity that causes seizures. This mechanism differs from other epilepsy drugs that typically focus on sodium channels (search).
The study participants were among the most treatment-resistant epilepsy (search) patients, typically already taking multiple anti-seizure drugs. Dr. Jacqueline French, a New York University neurology professor who helped conduct the trial, noted that patients were split into three groups: those receiving a daily 15 mg pill, a 25 mg pill, or placebo. All participants were monitored for more than two months to establish baseline seizure activity before beginning the 12-week study.
Unique Treatment Advantages
The drug offers several advantages over existing epilepsy (search) treatments. Unlike other anti-seizure medications, azetukalner doesn't require gradual dose increases over weeks, making it "easy, safe and fast," according to Dr. French. The medication can be taken once daily at night, minimizing the impact of side effects.
Jefferies analyst Andrew Tsai described the drug as having "produced one of the most compelling pivotal datasets in focal epilepsy (search)," predicting it could become a US$1 billion-plus per year seller. Doctors have "consistently endorsed azetukalner as a potential best-in-class epilepsy drug," he noted.
Long-Term Success Stories
The drug's effectiveness extends beyond clinical trials. Rick Bishop, a rural Pennsylvania retiree who participated in the 2021 study, has been seizure-free since the early 2020s after starting azetukalner. Previously experiencing multiple daily seizures requiring a service dog named Sailor, Bishop reported a "100% improvement" in his quality of life.
More than 10% of patients from the 2021 trial who participated in extended studies have reported no seizure activity at all since then. In follow-up studies, 25% of participants who continued using the drug were seizure-free over any subsequent 24-month period.
Development History and Market Path
Xenon's journey with azetukalner began through acquisition of rights from Valeant Pharmaceuticals International (search) (now Bausch Health Companies), which had developed the compound as an improved version of ezogabine, a potassium channel-modulating drug that was discontinued due to side effects including skin discoloration.
The company, co-founded by University of British Columbia geneticist Michael Hayden and Simon Pimstone in 1996, has raised US$1.4 billion to date. With positive trial results in hand, Xenon plans to submit its new drug application to the FDA in the second half of 2026.
Commercial Preparations and Funding
To prepare for commercial launch, Xenon filed a prospectus last month to raise up to US$400 million through an "at-the-market" offering. The company expects the drug to cost US$15,000-plus annually per patient, according to Needham & Co. analyst Serge Belanger.
If approved, azetukalner would become the 15th therapy developed in British Columbia to win regulatory approval, joining innovations from companies including QLT, Angiotech, AbCellera Biologics, and Acuitas Therapeutics.
The drug's most common side effects include dizziness, headache, sleepiness, and fatigue. Xenon is conducting additional studies to evaluate whether azetukalner can alleviate mood disorders and pain, potentially expanding its therapeutic applications beyond epilepsy (search) treatment.